Dr. Matthew Abramowitz, MD
Claim this profileUniversity of Miami
Area of expertise
Prostate Cancer
Matthew Abramowitz, MD has run 6 trials for Prostate Cancer. Some of their research focus areas include:
Prostate Adenocarcinoma
Matthew Abramowitz, MD has run 2 trials for Prostate Adenocarcinoma. Some of their research focus areas include:
Affiliated Hospitals
University Of Miami
Albert Einstein College Of Medicine / Montefiore Medical Center
Clinical Trials Matthew Abramowitz, MD is currently running
Sotagliflozin
for Diabetic Kidney Disease
Powerful new drugs that can prevent or delay end stage kidney disease (ESKD) - so called sodium-glucose cotransporter-2 inhibitors (SGLT2i) - are now available for patients with type 2 diabetes. Whether these drugs have similar effects in patients with type 1 diabetes (T1D) remains unknown because of the few studies in this population, due to concerns about the increase in risk of diabetic ketoacidosis (DKA, a serious, potentially fatal acute complication of diabetes due to the accumulation of substances called ketone bodies) observed with SGLT2i therapy in T1D. One of the few T1D studies conducted to date showed that implementing an enhanced DKA prevention plan can reduce the risk of DKA associated with the SGLT2i sotagliflozin (SOTA) to very low levels. In the present study, a similar DKA prevention program will be used to carry-out a 3-year trial to test the kidney benefit of SOTA in 150 persons with T1D and moderate to advanced DKD. After a 2-month period, during which diabetes care will be standardized and education on monitoring and minimizing DKA implemented, eligible study subjects will be randomly assigned (50/50) to take one tablet of SOTA (200 mg) or a similarly looking inactive tablet (placebo) every day for 3 years followed by 2-months without treatment. Neither the participants nor the study staff will know whether a person was assigned to taking SOTA or the inactive tablet. Kidney function at the end of the study will be compared between the two treatment groups to see whether SOTA prevented kidney function loss in those treated with this drug as compared to those who took the inactive tablet. The DKA prevention program will include participant education, close follow-up with study staff, continuous glucose monitoring, and systematic ketone body self-monitoring with a meter provided by the study. If successful, this study will provide efficacy and safety data that could be used to seek FDA approval of SOTA for the prevention of kidney function decline in patients with T1D and DKD.
Recruiting
1 award
Phase 3
Radiotherapy
for Prostate Cancer
The purpose of this research study is to learn about: 1) How standard radiation treatment to prostate (primary radiotherapy) or the pelvis after prostatectomy (postoperative radiotherapy) may cause changes in MRI and PET imaging traits that might be used in the future to predict response. 2) Comparison of such MRI and PET imaging traits with the number of circulating tumor cells (CTCs) present in the blood prior to treatment and the changes in these counts after treatment. 3) How MRI and PET imaging characteristics and changes are related to the expression of genes in the cancer tissue obtained before treatment from prostate biopsy or a prior prostatectomy before treatment. 4) How the response of prostate cancer treatment relates to the imaging and CTC changes.
Recruiting
1 award
N/A
10 criteria
More about Matthew Abramowitz, MD
Clinical Trial Related
1 year of experience running clinical trials · Led 8 trials as a Principal Investigator · 3 Active Clinical Trials
Treatments Matthew Abramowitz, MD has experience with
- Mapped Tumor Salvage RT (MTSRT)
- Standard Salvage Radiation Treatment (SSRT)
- Accelerated Hypofractionation Radiotherapy
- Extended Hypofractionation Radiotherapy
- 177Lu-PSMA-617
- 68Ga-PSMA-11
Breakdown of trials Matthew Abramowitz, MD has run
Prostate Cancer
Prostate Adenocarcinoma
Heart Failure
Cardiovascular Disease
Diabetic Kidney Disease
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Matthew Abramowitz, MD specialize in?
Matthew Abramowitz, MD focuses on Prostate Cancer and Prostate Adenocarcinoma. In particular, much of their work with Prostate Cancer has involved Stage IV patients, or patients who are Stage II.
Is Matthew Abramowitz, MD currently recruiting for clinical trials?
Yes, Matthew Abramowitz, MD is currently recruiting for 3 clinical trials in Miami Florida. If you're interested in participating, you should apply.
Are there any treatments that Matthew Abramowitz, MD has studied deeply?
Yes, Matthew Abramowitz, MD has studied treatments such as Mapped Tumor Salvage RT (MTSRT), Standard Salvage Radiation Treatment (SSRT), Accelerated Hypofractionation Radiotherapy.
What is the best way to schedule an appointment with Matthew Abramowitz, MD?
Apply for one of the trials that Matthew Abramowitz, MD is conducting.
What is the office address of Matthew Abramowitz, MD?
The office of Matthew Abramowitz, MD is located at: University of Miami, Miami, Florida 33136 United States. This is the address for their practice at the University of Miami.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.